Page 24 - Nature Structural News Today : Breaking News, Live Updates & Top Stories | Vimarsana

 E-Mail IMAGE: The background of the illustration is a photograph taken with the electron microscope showing DNA molecules decorated with MutS molecules, scanning the DNA for errors. The lower part shows... view more  Credit: CNIO Scientists from the Genomic Integrity and Structural Biology Group led by Rafael Fernández-Leiro at the Spanish National Cancer Research Centre (CNIO) have discovered how certain proteins ensure the repair of errors introduced into the DNA during its replication. Using cryo-electron microscopy, they made the MutS protein, also known as the guardian of ou...

 E-Mail IMAGE: This model shows the structure of the spike protein in its closed configuration, in its original D614 form (left) and its mutant form (G614). In the mutant spike protein, the... view more  Credit: Bing Chen, PhD, Boston Children's Hospital BOSTON - March 16, 2021 - The fast-spreading UK, South Africa, and Brazil coronavirus variants are raising both concerns and questions about whether COVID-19 vaccines will protect against them. New work led by Bing Chen, PhD, at Boston Children's Hospital analyzed how the structure of the coronavirus spike proteins changes with the ...

Posted on 7440 Wren Therapeutics Ltd., (“Wren”), a biopharmaceutical company pioneering a unique network kinetics approach to drug discovery for protein misfolding diseases, today announced the closing of a £12.4 million (c. $17.0 million) financing. This financing brings the total capital raised to date to approximately £33 million (c. $45 million). The financing was led by existing shareholder The Baupost Group, with participation from existing investors including LifeForce Capital and new investors including Schooner Capit...

Press release content from Business Wire. The AP news staff was not involved in its creation. Wren Therapeutics Announces Financing of £12.4 Million (c. $17.0 Million) January 25, 2021 GMT CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--Jan 25, 2021-- Wren Therapeutics Ltd., (“Wren”), a biopharmaceutical company pioneering a unique network kinetics approach to drug discovery for protein misfolding diseases, today announced the closing of a £12.4 million (c. $17.0 million) financing. This financing brings the total capital raised to date to approximately £33 million (c. $45 million). The fi...